News

Rising costs and evolving compound developments underline need for understanding at every step.

All ESC guideline task forces set to consider PROs in their recommendations

PROs must be included in cardiovascular clinical trials using the best available tools,according to leading cardiologists and industry representatives in the Cardiovascular Round Table.

KMR Group has completed its latest upload of current site performance data into the Site Scorecard Tool.

MCC released its new Metrics Search Engine

MCC continues to lead the industry in the development, adoption, and utilization of standardized metrics and tools to drive performance improvement.

KMR Group has just completed its latest upload of current site performance data into the Site Scorecard Tool.

Patients 65 years of age and over are underrepresented in clinical trials, even though in many therapeutic categories they are the primary drug consumers.

New Integrated Platform Streamlines, Guides Genomic Analysis for Clinical Trials

Omicia, Inc. announced that its clinical next-generation sequencing interpretation software will be used by LabCorp.

We compiled a list of how sponsors offer access to patient level clinical data requests from researchers.

Eli Lilly and Company announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com.

Will conduct the first comprehensive in-depth analysis of outsourced clinical research quality.

While at the 2014 New York BIO Conference, I had the opportunity to interview Nathan Tinker, Executive Director at the New York Biotechnology Association, about challenges in early phase development.

Thomson Reuters Cortellis Competitive Intelligence

Clinical trial optimization through adaptation in several key areas was a prevailing message at the recent Partnerships Conference.

Congressional leaders have launched a major initiative to revise laws and regulatory policies to speed new cures to patients.

S

CRO/Sponsor: High Performing Study Startups Sites: RBM Challenges, Opportunities Trial Design: Three-pronged Monitoring Approach Study Recruitment: Enhancing Trial Enrollment Also in this issue: New EU Drug Legislation The Patient Experience Rebranding RBM

Drug development in oncology has some of the lowest rates of success and clinical trials in oncology are difficult because of recruitment, challenging protocols and multiple technologies used to evaluate drugs in trials. This eBook contains information on these challenges including Phase I trials, to improving recruitment and trends in oncology clinical trials.

This commemorative e-book includes special articles, as well as DIA session highlights and news that pharmaceutical and clinical trial professionals will find important and informative.

NAPF is launching its Project Innovation, a national movement to accelerate the pace of cancer medical discovery.

Project Innovation Launched to Drive Action

The WIRB-Copernicus Group announced it has formed a new cancer-focused institutional review board, WCG Oncology.

inVentiv Health Clinical and Advaxis, Inc. announced they have entered into a global master services agreement...

A European bid to impose additional limits on research involving human embryos has been defeated.

The WIRB-Copernicus Group announced today the formation of a new cancer-focused institutional review board, WCG Oncology

Redacted policy on sharing drug trial data in Europe.

If the EMA also stops releasing data on old trials, everybody will be kept even more in the dark, according to an editorial posted by bmj.com on May 28.

Celerion and the Korean Drug Development Fund announced a formal collaboration